NATHBIOGEN Nath Bio-Genes (India) Q4 FY26 results (Jan–Mar 2026) and concall
Nath Bio-Genes reported a strong Q4 FY26 with 19% YoY revenue growth to INR 431.6 crores, driven by robust performance in cotton, paddy, and particularly maize. While gross margins normalized from previous highs and PAT saw an 8% decline due to increased tax rates and finance costs, the company highlighted strategic diversification, successful international expansion with its Uzbekistan JV contributing INR 15 crores, and a healthy product pipeline. Management expressed confidence in continued growth despite environmental challenges like El Nino, emphasizing a balanced portfolio and distributio
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue down 6.1%, net profit down 20.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 32 | 37 | 49 | 280 | 40 +25% | 66 +78% | 46 −6% |
| EBITDA | 7 | 8 | 3 | 30 | 7 +0% | 9 +13% | 7 +133% |
| Net profit | 3 | 3 | 5 | 29 | 4 +33% | 7 +133% | 4 −20% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
